Zilebesiran in combination with a diuretic in patients with uncontrolled hypertension: a subgroup analysis from the Phase 2 KARDIA-3 trial
Despite availability of oral antihypertensive therapies, most patients do not achieve hypertension (HTN) control. Zilebesiran is an investigational RNA interference therapeutic, dosed subcutaneously (SC) every 6 months to lower production of hepatic angiotensinogen (AGT), the most upstream precursor of the renin–...